An ongoing clinical trial is evaluating safety and activity of the combination of osimertinib + alisertib or sapanisertib (an oral inhibitor of TOR complex 1 and 2) in osimertinib-resistant EGFR-mutated lung cancer (NCT04479306). The gene discussed is EGFR; the disease is lung carcinoma.